X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

MedPharm Ltd signals growth intentions with appointment of Eugene Ciolfi as President and CEO

Content Team by Content Team
28th November 2018
in Americas, News
MedPharm Ltd signals growth intentions with appointment of Eugene Ciolfi as President and CEO

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

MedPharm Ltd is pleased to announce that Eugene Ciolfi has joined as its President and Chief Executive Officer. In conjunction with his hiring, he has also been appointed to MedPharm’s Board of Directors.

Gene joins MedPharm with over 25 years of experience in the development and manufacturing of pharmaceutical drug products in semi-solid, liquid and other, alternative dosage forms. His previous experience includes having served in a variety of manufacturing, commercial operations and general management positions at DPT Laboratories. Most recently, for the past two years, Gene served as Site Head of Torrent Pharma’s FDA/DEA Class II-V approved non-sterile liquid and semi-solid development and manufacturing operation.

Gene is charged with driving MedPharm’s growth further downstream into commercial manfacturing and opening up additional markets based on the company’s unique performance modelling, formulation development and manufacturing expertise.

Dr. Andy Muddle, Co-founder of MedPharm who has served as its CEO for the past 19 years, will remain with the Company in an ambassadorial role. He has been actively involved in many of the decisions that have been fundamental to MedPharm’s success. Dr. Muddle will continue to provide support to the commercial team and remain focused on strategy and commercial development, in addition to continuining to serve on the Company’s Board of Directors.

Professor Marc Brown, Co-founder and Chief Scientific Officer commented, “MedPharm’s unique position in the topical and transdermal formulation development arena, along with Gene’s know-how and experience, makes for a winning combination. I would like to congratulate him as he steps into his new role, and we look forward to supporting him as he expands MedPharm’s offering.”

Ampersand General Partner and MedPharm Board Member David Parker added “Gene’s decades of relevant industry experience and impressive track record make him ideally suited for the MedPharm CEO position. We are extremely pleased that he will be leading the Company as it moves to expand its manufacturing capabilities and deliver on its ambitious growth plans.”

About MedPharm
MedPharm Ltd. is a leading, global provider of contract topical and transdermal product design and formulation development services. MedPharm are experts at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through the use of proprietary, industry-leading performance testing models. Well-established as a global leader in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm also offers innovative solutions for ophthalmic and airway preparations. These solutions are recognised for their scientific rigor by regulators and investors. MedPharm has fully established R&D centres in the US and UK and GMP clinical manufacturing at its global headquarters facility in Guildford, UK. For more information visit our website www.medpharm.com

Previous Post

Pharmintech 2019: Big increase in International Participation Expected

Next Post

AMAL Therapeutics raises CHF 33.2 Million Series B Round

Related Posts

FDA Accepts BLA for Recommended
FDA Approvals

FDA Accepts BLA for Recommended Biosimilar to Simponi

22nd July 2025
Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
Next Post
AMAL Therapeutics raises CHF 33.2 Million Series B Round

AMAL Therapeutics raises CHF 33.2 Million Series B Round

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In